Introduction
Chronic granulomatous disease (CGD) is an innate, inherited, heterogeneous, immunodeficiency disorder that renders patients susceptible to recurrent, severe pyogenic bacterial and/or fungal infections and excessive hyperinflammatory responses with eventual granuloma formation and premature death [1] . The incidence varies from 1:1 million in Italy to 1:143,000 in Denmark [2, 3] . The disease affects phagocytic cells, such as neutrophils, eosinophils, monocytes, and macrophages, rendering them incapable of effectively killing phagocytized microorganisms. Figure 1 is a schematic of the neutrophil effector functions required to achieve adequate primary immune defense [4] .
Genetic defects of nicotinamide adenosine dinucleotide phosphate (NADPH) reduced oxidase components are known to cause CGD. These genetic defects lead to significantly decreased reactive oxygen species (ROS) production, which plays a pivotal role in microbial killing. Mutations affect one of the five genes (CYBB, CYBA, NCF1, NCF2, and NCF4) that encode structural components of the NADPH oxidase protein (gp91 phox , p22 phox , p47 phox , p67 phox , and p40 phox , respectively). The gp91 phox and p22 phox proteins are located in the cell membrane and together form the flavocytochrome b 558 of the NADPH oxidase. During phagocytosis, the cytosolic NADPH oxidase subunits p47 phox , p67 phox , and p40 phox translocate to flavocytochrome b 558 in the phagosomal membrane, inducing a conformational change that allows NADPH to donate electrons to gp91 phox . This leads to the generation of superoxide in the phagosome, from which other ROS such as hydrogen peroxide may be formed [5, 6] . Defects in gp91 phox are an X-linked recessive (XLR-CGD) inheritance and are found in approximately 70% of CGD patients, who have the most severe phenotype. The autosomal recessive forms of CGD (AR-CGD) are due to mutations in the CYBA gene on chromosome 16 (5% of patients), the NCF1 gene on chromosome 7 (20%), the NCF2 gene on chromosome 1 (5%), or the NCF4 gene on chromosome 22 (one patient reported) [7] . In addition to the classic X918 CGD in which gp91 phox is totally absent, variant forms of XLR-CGD have been described as X91
-and X91
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, that is, expression of partially functional or nonfunctional gp91 phox , respectively. In the past, CGD was considered a severe, lethal disorder of childhood [8] . Today we know there are milder forms with long-term survival [9] [10] [11] [12] [13] [14] . Patients may develop severe, chronic manifestations, such as failure to thrive (FTT), anemia, chronic lung disease (CLD), gastrointestinal disturbances, and hyperinflammatory states causing granuloma formation, which eventually result in obstruction and chronic insufficiency of the affected organ system [15] .
In recent decades, with the rapid development of sophisticated diagnostic tools and techniques, knowledge of the genetic basis of CGD has progressed and its clinico-pathological expression is better understood, improving prognosis [16] . The new arsenal of antibiotics and antifungal drugs allows better disease management and improved quality of life [17, 18] . Results with interferon gamma have been controversial [2, 19] . Allogeneic hematopoietic stem cell transplantation (HSCT) is the definitive treatment for CGD [20, 21] . It should be performed as soon as possible in severely affected patients, to prevent irreversible tissue damage. Gene therapy could be an alternative to a definite cure, but additional investigations are needed to prove the efficacy of this approach [22, 23] .
Over the course of 30 years, patients with recurrent, severe, pyogenic bacterial and/or fungal infections were referred to our laboratory to identify underlying phagocytic disorders. The advanced medical facilities in Israel and efficient communication between hospitals and community clinics, allow immediate referrals for CGD diagnosis and management, including prenatal diagnosis. In our previous study, primary phagocytic disorders were identified in 57/998 (5.7%) of referred patients, among which 48 had CGD [24] . In the last 10 years, the incidence has increased due to the large immigration of Jews from disparate countries, increased medical team awareness and community education programs, noting symptoms that should be evaluated for CGD.
This study summarizes the clinical, functional, molecular and genetic experience of managing CGD patients in Israel to date. We also investigated whether the specific genetic mutation and the level of residual ROS affect disease severity and can predict clinical outcomes. 
Methods
CGD was diagnosed by assessing ROS production by using the dihydrorhodamine-1,2,3 (DHR) assay for measuring hydrogen peroxide generation and the superoxide dismutase-inhibitable reduction of ferricytochrome c assay for measuring superoxide production. Bactericidal activity was also evaluated as additional tool for assessing clinical severity.
Neutrophil isolation. Neutrophils were isolated by Ficoll-Histopaque sedimentation, followed by erythrocyte lysis [25] . Neutrophils were washed and resuspended in phosphate-buffered saline with 1% (v/v) bovine serum albumin. Cell purity was 99% and viability > 95%.
Reactive oxygen species formation. Superoxide release rate was measured using the Weisbart et al. method [26] in a UV-260 Shimadzu spectrophotometer (Shimadzu, Kyoto, Japan) at 550 nm and was calculated with the Massey extinction coefficient for ferrocytochrome c of 2.1 3 10 4 M 21 cm
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. Normal superoxide values were >1.2 nmol O 2 2 /10 6 cells/min. Neutrophil hydrogen peroxide assay with DHR was conducted as described by Vowells et al. [27] . In brief, neutrophils were incubated with DHR (Sigma, St. Louis, MO) and catalase, and activated with 100 ng/ml phorbol myristate acetate. The reaction was stopped after 15 min and the amount of the DHR oxidation product rhodamine-1,2,3 was measured by flow cytometry. The stimulation index (SI) was calculated by dividing the mean fluorescence units (MFU) of stimulated neutrophils by the MFU of unstimulated neutrophils. Normal SI was >70% of healthy controls. SI <3 was considered "null ROS" and SI 3 was considered "residual ROS."
It is of note that AR-CGD carriers cannot be detected with these methods, as they may have normal superoxide and hydrogen peroxide production. In contrast, carrier mothers of XLR-CGD patients usually have both normal and abnormal neutrophil populations, detectable in the DHR assay.
Bactericidal activity. Bactericidal activity (BA) was assessed as previously reported [28] and expressed as the decrease in the number of viable bacteria. Bacteria (S. aureus, 502A, ATCC, Rockville, MD) were incubated with neutrophils (3:1 ratio) in the presence of autologous and homologous serum. Normal values were >0.5 log decrease of colonies per hour.
Immunological and genetic studies. Western blot analysis was performed for protein analysis of the NADPH-oxidase system. Neutrophil lysate (20 lg) was electrophoresed in 10% (w/v) SDS-polyacrylamide gel and transferred to a nylon membrane. The membrane was incubated with mouse monoclonal antibodies against gp91 phox or p22 phox [29] or with specific rabbit polyclonal antisera to p47 phox or p67 phox [30] . Alkaline phosphatase-conjugated anti-mouse or anti-rabbit immunoglobulin was used to detect antibody binding to the blot.
DNA was purified from leukocytes by standard methods. PCR amplification and sequence analysis of CYBA, CYBB, NCF1, and NCF2 exons with their intron/exon boundaries and 400 basepairs of the CYBB promoter region were performed as described previously [31, 32] . Sequence data analysis was performed with Ion Reporter Software (Thermo-Fisher Scientific, Waltham, MA). Deep sequencing was performed using Ion Torrent Targeted Sequencing. An Ampliseq TM custom panel (ThermoFisher Scientific) was used to sequence the coding regions of CYBB, CYBA, NCF1, NCF2, and NCF4. Library preparation and sequencing was performed according to manufacturer protocols on a PGM or Ion S5 system (Thermo-Fisher Scientific).
Statistical Analysis
SPSS, version-23 (SPSS, IBM, NY) was used for statistical analysis. Student's t test (or Mann-Whitney U test for nonparametric conditions) was used to compare continuous variables. Pearson or Spearman correlations were analyzed between continuous variables, each when appropriate. Kaplan-Meier graphs were used to show survival rates, including patients who were alive at last follow-up. P-values <0.05 were considered statistically significant.
Results
CGD was suspected on clinical grounds and confirmed in all patients by functional, molecular and genetic studies. Eighty-four patients from 61 unrelated families of various ethnic origins were diagnosed with CGD. There were 67 males and 17 females, with a median age at diagnosis of 4 years (1 month to 74 years). Forty-four were of Jewish descent and 37 were of Arab descent, including 21 from the Palestinian Authority (Table I) . Three additional patients were non-Jewish tourists from Russia referred to our laboratory for evaluation. The disease was diagnosed in Jewish patients from Ashkenazi, Sephardic, and Oriental ethnic origins. Ashkenazi Jewish patients had the XLR form, while Sephardic and Oriental Jewish patients had both XLR and AR-CGD forms.
In the last 7 years, with the inclusion of 46 new CGD patients in the study, the incidence of CGD in Israel has increased considerably. It is estimated at 1.17 per 100,000 live births (95%CI 0.78-1.72), that is, 1.05 per 100,000 live births in the Israeli Jewish population (95%CI 0.64-1.65) and 1.49 per 100,000 live births in the Israeli-Arab population (95%CI 0.79-2.82). For more details, see Supporting Information Appendix (Table S1 ). Arabs living in the Palestinian Authority were not included in the statistical evaluation, because registry data are not available. Of note, from November 2015 to July 2016, seven additional CGD patients were diagnosed (totaling 91 CGD patients), but they were not included in the statistical analysis.
Clinical manifestations
Most CGD patients had pyogenic infections since early infancy. Catalase-positive and opportunistic microorganisms (bacterial, fungal) were the most common etiological agents (Table II) . In this series, S. aureus and Aspergillus spp. were isolated in most patients with pneumonia, suppurative adenitis, skin/subcutaneous abscesses, liver/spleen abscesses and bone infections. S. marcescens was isolated from suppurative adenitis, skin/subcutaneous abscesses, lung, and bones. Candida spp. was isolated from skin, mucous membranes, brain abscesses, ventriculitis, and meningoencephalitis. The pathogens associated with hematogenous sepsis were gram-negative spp., Klebsiella spp., E. coli, Salmonella spp., P. aeruginosa, B. cepacia. Also gram-positive bacteria, such as S. aureus, and mycotic agents such as Candida spp. and Aspergillus spp., were isolated in sepsis. Aspergillus spp. were isolated in 29 patients, 13 with XLR-CGD and 16 with AR-CGD; one patient had multiorgan Aspergillus infection, 22 in the lung (76%), three in the brain, three in the bones, two subcutaneous, and one periodontal. Aspergillus septicemia was detected in 11 patients, eight of whom died. The patients with Aspergillus pneumonia who died presented with significant acute inflammatory response, hypoxemia, cyanosis, disseminated pulmonary infiltrates and necrotizing granulomas. Nocardia was isolated in three patients (4%); from pneumonic abscess, brain abscess and axillar abscedated lymphadenitis.
We detected two patients with generalized tuberculosis, one from Gaza and one from Russia who were treated successfully with antituberculosis drugs. Mycobacterium tuberculosis was previously research article reported in CGD patients in endemic areas, such as Iran, Africa, China, and Latin America [33] [34] [35] [36] . In addition, following vaccination with the Bacille Calmette-Guerin (BCG; attenuated mycobacterial bovis) CGD patients may develop adverse reactions, such as BCG-itis, usually a local inflammation, although sometimes developing into disseminated tuberculosis. We detected two patients with localized BCG-itis, referred from the Palestinian Authority.
Abscesses were located in the liver (39%), lung (36%), perianal (18%) and less commonly in the brain (5%) and kidney (4%) (Supporting Information Table S2 ). Granulomas involving one or more organs were detected in 68% of patients, including liver (39%), lung (25%), central nervous system (CNS; 5%), urinary tract outflow (5%), intestinal (5%), esophageal (4%), gastric (1%) bladder (1%), and testicles (1%). Achalasia and gastric pyloric stenosis were found in one patient each and granulomas imitating Crohn's disease were found in two patients. Gastrointestinal tract, genitourinary tract and CNS obstructions occurred in 17% of patients, leading to intestinal malabsorption, hydronephrosis, and hydrocephalus, respectively. In line with others, steroids for granuloma obstruction were administered to 32%, resulting in rapid clinical response [37] .
The most common chronic manifestations were anemia of chronic infection (65%), lymphadenopathy (52%), FTT (45%), hepatosplenomegaly (25%), and gastrointestinal disturbances in about 25% of patients. Short stature and underweight were seen in patients with high clinical severity scores. Similar to our data on FTT among children with CGD, the Japan National Center for Child Health, and Development reported that children with CGD had remarkable growth retardation, which correlated with disease severity [38] .
A particular patient was a woman who was 66 years of age at disease onset. Over a period of 8 years she had 30 admissions to different hospitals, until the diagnosis. Her laboratory studies showed a very unusual form of somatic XLR-CGD at the age of 74 years, as previously reported by our group [39] . She suffered from chorioretinitis, uveitis and recurrent, severe pyogenic infections such as suppurative adenitis, pneumonias, deep-subcutaneous, and liver abscesses. Notably, the clinician's awareness led to this diagnosis. The patient received prophylactic treatment for CGD and died at 85 years of natural causes.
Malignancies were reported in CGD [40, 41] . We found T-cell acute lymphoblastic leukemia (ALL) in a XLR-CGD patient [42] and carcinoma of the uterine cervix in a 25-year-old woman with AR-CGD. The ALL patient was diagnosed at 4 months of age and despite his immunodeficiency, aggressive chemotherapy therapy was successfully given. He died at 21-year-of-age during preparation for HSCT due to end-stage respiratory failure secondary to CLD. The patient with cervical carcinoma was diagnosed as AR-CGD soon after birth. Following recurrent, relapsing lung infections she died at the age of 28 year due to end-stage respiratory failure.
Neutrophil functions and genetic studies
Cytochrome c was assayed in 82 patients, while DHR and BA were assayed in 60. CGD was confirmed genetically in all patients. All patients tested had null superoxide production with various levels of H 2 O 2 production (SI in the DHR assay) and BA. SI levels correlated with the neutrophil BA (r 5 0.42, P < 0.01) and with clinical scores, indicating disease severity (r 5 20.30, P < 0.05).
Higher SI levels correlated with better prognosis. Indeed, a positive correlation was found between SI levels and age at disease onset (r 5 0.44, P < 0.0001), age at diagnosis (r 5 0.63, P < 0.0001) and the interval between onset and diagnosis (time without prophylactic treatment; r 5 0.63, P < 0.0001). Characteristics of patients with high versus low SI were evaluated. Sixty patients who underwent the DHR assay were divided according to SI levels: null ROS (SI < 3, n 5 38) and residual ROS (SI 3, n 5 22; Supporting Information Table S3 ). Patients with null ROS had significantly earlier disease onset and diagnosis than those with residual ROS. The null ROS group included significantly more patients with X918, nonsense mutations, higher clinical severity scores and greater tendency to granuloma formation. Missense mutations were found in significantly more patients with residual ROS, indicating a better prognosis (Supporting Information Table S3 ). No statistical significance was found in life expectancy between groups, although mean survival in the null group was remarkably lower (29.6 6 2.7 years [SE]) versus the residual group (61.0 6 2.9; P 5 0.35, Supporting Information Table S3 ; Fig.  S1 ). Gender and ethnic origins in the groups were similar.
Looking for a link between SI levels and molecular subtypes revealed distinct associations. Those with X918 had greatly diminished SI (1.6 6 0.2, 2% of control), significantly impaired BA and a severe clinical score, while those with X91 -showed moderately decreased SI (37 6 6.4, 30% to 50% of controls) with null superoxide production, but normal BA and better clinical score (P < 0.05) [43] .
In the AR group, SI levels were also reduced, but were significantly higher in the A478 subtype (4.2 6 0.6) and with a better clinical score (P < 0.005; Table II ). This is due to the assay: when p47 phox is lacking, some electrons are directly shuttled from the FAD prosthetic group in gp91 phox to oxygen, thus directly generating some H 2 O 2 [44] . This was identified by the DHR assay, but not by cytochrome c. It seems that small amounts of ROS are sufficient to cope with infections.
Of the 84 patients diagnosed, 52 (62%) from 36 unrelated families had the AR-CGD subtype and 32 (38%) from 25 unrelated families research article
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had the XLR-CGD subtype. In the AR form, we found three subtypes: A228 (10 patients), A678 (16 patients), and A478 (26 patients; Table II ). In the X-linked form, we found three subtypes of X91: X918 in 27 patients (22 unrelated families), X91 -in 3 (one family), and X91
1 in 2 (two unrelated families). The prevalence of the XLR and AR groups differed significantly (P < 0.005), emphasizing the high rate of AR inheritance in Israel, which relates to the high rate of consanguinity (64%) among the AR-CGD offspring from Jewish or Arab origin (14% and 50%, respectively), but not in families of XLR-CGD patients.
The median age at diagnosis in the XLR-CGD group was 3.2 years (3 months to 74 years) and 4.2 years (1 month to 40 years) in the AR-CGD (P < 0.003). The median age at onset of clinical expression in the XLR-CGD group was 0.9 years (1 day to 66 years) and 2.0 years (1 day to 22 years) in AR-CGD (P < 0.0003). Onset of infections under age 1 year occurred in 45 (54%), of whom 41 (92%) belong to the more severe XLR-CGD group.
As expected, the XLR group included mostly males (97%), but a predominance of males (69%) in the AR-CGD group was observed, unexpectedly.
Thirty-six different mutations in 136 alleles were found in the four genes causing CGD, with 15 new mutations, five de novo mutations and one somatic mutation (Supporting Information Table S4 ). In the CYBB gene, we found 23 different mutations, among them 11 new, five de novo and one somatic. In the AR group, we found 13 different mutations: five (2 new) in CYBA, four in NCF1, and four (2 new) in NCF2. Mutations included nonsense (32), missense (17) , deletions (18) , insertions (15) , and splice site mutations (2) . Remarkably, no splice site mutations were found among 32 XLR-CGD patients (Supporting Information Tables S5-S8) .
Conventional techniques could not determine the genetic carrier state in two mothers of XLR-CGD patients. Using new generation deep sequencing, we detected the mutation in both mothers, in 3% and 16% of their leukocyte DNA, respectively. This indicates that a somatic mutation was passed on to their children, despite the very low probability.
The mutations identified in the AR-CGD patients were homozygous in 49 of 36 families, indicating that both parents contributed an identical, mutated allele that caused the disease. However, three patients in two unrelated families were compound heterozygous for two mutations in the NCF1 gene.
Treatment
Patients were prophylactically medicated with trimethoprimsulphamethoxazole (83%) and itraconazole (54%) or voriconazole (35%). Percutaneous or excisional drainage surgery was required in 52% of patients with large, suppurative abscesses unresponsive to adequate intravenous antibiotics.
Recombinant human interferon-gamma (rIFN-g) was given to nine patients over 1 year, with limited response. The effectiveness of this modality is controversial. Martire et al. did not find significant difference in the rate of infections per patient-year between patients treated with or without rIFN-g. Furthermore, most of those receiving rIFN-g had adverse effects, including fever, myalgia, headache, fatigue and rash, leading to its discontinuation [2] .
HSCT was performed in 21 patients, 16 received a fully matched sibling donor transplant (MSD), two a fully matched unrelated donor transplant (MUD), two a haploidentical donor transplant, and an additional patient had an unsuccessful MUD followed by an unsuccessful haploidentical transplant. Successful engraftment was achieved in 18 patients; half received myeloablative therapy with Busulfan/ Cytoxan chemotherapy combined with serotherapy (ATG) and half received reduced-intensity conditioning with Fludarabine-Thiotepa and targeted Busulfan-Treosulfan, combined with ATG. Graft versus host disease developed in five patients and resolved following treatment. Three patients, who had the AR subtype and underwent a MSD transplant died post-HSCT; one from S. aureus sepsis one month post-HSCT; another after 6 years from S. aureus sepsis and the third after 8 years following unsuccessful lung transplantation. All surviving patients are alive and well, with no evidence of CGDrelated infections in 94% (Supporting Information Table S9 ). Of note, all nine patients who underwent HSCT before age 8 (2-7 years) are alive and well (Supporting Information Fig. S2 ).
Outcome CGD variants presented with unique clinical and laboratory expressions and varying life expectancies. The mean overall survival (OS) was 35 6 2.69 years, 21 6 2.81 years with the X918 form and 38 6 3.81 years with the AR form (Table II, Fig. 2a) . The mean survival of the X918 and A678 subtypes was significantly less than that of the A478 subtype (P < 0.005; Fig. 2b) .
Among deceased patients, the median age at disease onset was 5 months (1 month to 22 years) and median age at death was 16.0 years (6 months to 47 years). Their mean SI was 1.65 (SD 6 0.71) and mean clinical severity score reached 3.81 (SD 6 0.54). Causes of death were CLD, sepsis, or a combination. Death from septicemia was caused by Aspergillus spp., C. albicans, S aureus, P. aeruginosa, and Salmonella spp. (Supporting Information Table S10 ).
Miscellaneous
OS in the 46 CGD patients diagnosed in 2008-2015 was significantly higher compared with the earlier series of 38 patients, emphasizing the progress achieved in medical management (Fig. 3) . The mortality rate during the last 8 years was 2.2% in the new cohort (1/ 46) compared to 10.5% in the earlier cohort (4/38; P< 0.005). No significant differences were found between groups in ages at onset and diagnosis, as well as genetic subtypes and mutation types. The increased clinical severity and the decreased SI were in line with the higher mortality found in the earlier group (Supporting Information  Table S11 ).
Outstandingly, 12 CGD patients married, and 14 of 26 offspring were evaluated. Carrier state was found in 4, and 10 had normal genotype. One grandchild had CGD.
Discussion
CGD is a rare disorder with varying incidence across countries. It affects multiple ethnic groups with diverse genetic, cultural and environmental backgrounds. Israel is a small country with a multiethnic, heterogeneous population, in which the disease characteristics are well-reflected.
The significant prevalence of the AR over the XLR form is related to the high rate of consanguinity, also reported among CGD patients in North Africa, the Arab world, and Turkey [45] [46] [47] . Ashkenazi Jews, influenced by European cultural habits, have a low rate of consanguineous marriages, leading to the prevalence of XLR-CGD in this ethnic group. Another factor contributing to the AR-CGD predominance in Israel was the founder effect encountered in the Kavkazi Jewish population for the mutation c.579G > A, in the NCF1 gene [48, 49] .
Eighty percent of the patients were male, despite a high rate of the AR form. The male to female ratio in the AR inheritance should be similar as worldwide (48-57%) [11, 47, 50, 51] . However, in the present study we found 69% males with the AR-CGD form, probably due to the sample size.
The distinctive clinical manifestations of CGD are recurrent, suppurative infections caused by catalase positive and opportunistic microorganisms. The spectrum of pathogens in CGD is wide and not easily isolated in every infectious event. Blood, urine and sputum should be cultured. Chest CT scans are useful for detecting early pneumonia when radiographs are noncontributory. Cultures are recommended before instituting treatment, to target the precise etiological agent. In particular cases, fine needle aspiration, biopsy material or broncho-alveolar lavage should be done.
Similar to the Eastern world, gram-negative infecting organisms were more common in our area than in the Western world [17] . In Israel, Nocardia spp. infections are uncommon, while in North America they are frequently isolated in CGD [18] . Fungal infections are highly pathogenic, eliciting an exuberant inflammatory response. Aspergillus infection was the leading cause of death in our study as in others [9, 17, 52] and should be diagnosed promptly to initiate aggressive treatment. We detected two patients with BCG-itis. BCG vaccination is mandatory in endemic countries and is administered in the neonatal period. For the last 34 years, BCG is no longer given to Israeli newborns, except to exposed patients or those coming from virgin areas, such as Ethiopia. We suggest screening newborn infants from endemic areas for CGD before vaccination.
The excessive inflammatory reaction and prolonged infections that never completely resolve lead to granuloma formation with reduced neutrophil apoptosis and efferocytosis, imbalance of innate immune receptors and induction of highly proinflammatory Th17 cells [15] . The absence of ROS in phagocytic CGD cells results in exaggerated TNF-a production with inflammasome activity [53, 54] . Granulomas in the lung were associated with pulmonary necrosis, abscedation, fibrosis and bronchiectasis, which eventually resulted in CLD in 25% of patients in this study. The good response to low doses of steroids supports the inflammatory etiology of the granuloma.
The excessive inflammation and immune responses in CGD could also lead to autoimmune diseases, including systemic lupus erythematosus (SLE), discoid lupus, chorioretinitis, and immune thrombocytopenic purpura, as found here. Similar to others, we found other related immune conditions associated with CGD, such as sarcoidosis, inflammatory bowel disease (IBD), immune gastroduodenitis, and celiac disease [55, 56] . This validates the concept that innate impaired immunity, as with neutrophil dysfunction, can elicit conditions associated with hyperinflammation and immune diseases.
Diverse numbers of mutations in the XLR and AR forms were detected. In the CYBB gene, more than 680 different mutations have been recorded worldwide, 133 in the AR form, with 55 in the CYBA gene, 24 in the NCF1 gene and 54 in the NCF2 gene [57, 58] . Accordingly, we found 23 different mutations (11 new) in XLR-CGD patients and 13 different mutations (4 new) in AR-CGD patients. The CYBB gene has more mutations than the AR genes and new mutations are frequently reported. In XLR-CGD, each new mutation has a 50% chance of resulting in a new patient, whereas in AR-CGD, both parents need to be carriers, and even then only one in four children will be affected. The mutation rate could be the same, but the detection is much higher in XLR-CGD.
A link between the genetic and clinical expressions of the disease was found in patient groups, but not in individual patients [10] [11] [12] [13] [14] . In accordance with other reports, in the different XLR (X918, X91 -, X91 1 ) and AR subtypes (A228, A478, A678), residual ROS production can predict disease course and prognosis [50, 59] . In line with Kuhns et al., we found that patients with missense mutations showed significantly higher rates of residual ROS formation, while patients with nonsense mutations had severe clinical disease, poorer prognosis and lower SI than other groups [59] .
Among individual patients the correlation between the genotype and the clinical course of CGD is less predictable. Indeed, 15 Kavkazi patients with the same NCF1 gene mutation and six patients from Gaza who had the same mutation in the NCF2 gene, presented with exceptionally dissimilar clinical expression, from mild to severe disease. Further, other factors such as environmental conditions and medical care could also affect the disease course.
Trimethoprim-sulphamethoxazole along with antimycotic drugs is effective prophylaxis [60] [61] [62] . Nonetheless, prophylactic therapy and prompt antimicrobial treatment do not completely prevent infections and other complications that seriously affect quality of life. Newer therapeutic options for bacterial and fungal infections significantly improve therapeutic management. Immunizations are cornerstones of treatment.
Allogeneic HSCT is the only definitive treatment for CGD and has been performed using myeloablative or nonmyeloablative conditioning with promising results [20, 21, [63] [64] [65] . Reduced-toxicity conditioning might be sufficient, but the type of myeloablation should be adjusted relative to disease severity and patient response. Although the definitive indications and optimum time for HSCT are controversial, there is consensus that patients with poor prognosis and lifethreatening infections are definite candidates for early transplantation. Nevertheless, successful engraftment does not always assure a good prognosis or prevent late morbidity and mortality. The prolonged tissue damage and the secondary CLD with extensive fibrosis, granuloma formation and pulmonary bronchiectasis, seem to be a determining factor in patient mortality pre-and post-HSCT. As seen here, three patients died post-HSCT due to severe infections from one month to 8 years after the procedure. Consequently, HSCT should take place as soon as possible to avoid chronic complications and sequelae from infection and excessive inflammation. Here and as in other studies, it seems that OS post-HSCT is comparable to that of non-HSCT [66, 67] , although quality of life is much improved in the transplanted patients.
Gene therapy may prove an alternative treatment. Complete correction of circulating neutrophils is unnecessary because reduced oxidase activity seems to provide sufficient protection against infections [22, 23, 68, 69] .
Compared to our previous study, cumulative survival increased from 74% to 81% [10] . The OS rate of CGD in Israel is similar to that reported in European countries (80% to 85%).
In summary, ethnic and cultural factors influence the incidence of CGD worldwide. It seems that the affected NADPH-oxidase component and function are determining factors in the clinical manifestations of the disease and patient outcomes. Following better understanding of the molecular genetics, biochemical and immunological basis of CGD, new treatment strategies are evolving and the prognosis and quality of life have improved substantially.
Considering the numerous unknown factors influencing CGD expression, we can conclude that it is a genetically, biochemically and clinically heterogeneous condition. Environmental factors such as sanitation, socio-economic conditions, and medical services are determining factors in prognosis and outcome. Further investigations should be conducted to reveal the mechanisms behind the variability of disease expression.
